NO20020758D0 - N<o>6</o> heterocykliske substituerte adenosinderivater - Google Patents

N<o>6</o> heterocykliske substituerte adenosinderivater

Info

Publication number
NO20020758D0
NO20020758D0 NO20020758A NO20020758A NO20020758D0 NO 20020758 D0 NO20020758 D0 NO 20020758D0 NO 20020758 A NO20020758 A NO 20020758A NO 20020758 A NO20020758 A NO 20020758A NO 20020758 D0 NO20020758 D0 NO 20020758D0
Authority
NO
Norway
Prior art keywords
heterocyclic substituted
adenosine derivatives
substituted adenosine
sub
substituted
Prior art date
Application number
NO20020758A
Other languages
English (en)
Other versions
NO322459B1 (no
NO20020758L (no
Inventor
Robert T Lum
Jurg R Pfister
Steven R Schow
Michael M Wick
Marek G Nelson
George F Schreiner
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20020758L publication Critical patent/NO20020758L/no
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Priority to NO20020758A priority Critical patent/NO322459B1/no
Publication of NO20020758D0 publication Critical patent/NO20020758D0/no
Publication of NO322459B1 publication Critical patent/NO322459B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20020758A 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament. NO322459B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08702234 US5789416B1 (en) 1996-08-27 1996-08-27 N6 mono heterocyclic substituted adenosine derivatives
PCT/US1997/014724 WO1998008855A2 (en) 1996-08-27 1997-08-20 N6 heterocyclic substituted adenosine derivatives
NO19990787A NO312679B1 (no) 1996-08-27 1999-02-19 N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Publications (3)

Publication Number Publication Date
NO20020758L NO20020758L (no) 1999-02-19
NO20020758D0 true NO20020758D0 (no) 2002-02-15
NO322459B1 NO322459B1 (no) 2006-10-09

Family

ID=24820367

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19990787A NO312679B1 (no) 1996-08-27 1999-02-19 N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO19990787A NO312679B1 (no) 1996-08-27 1999-02-19 N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater

Country Status (25)

Country Link
US (1) US5789416B1 (no)
EP (3) EP0920438B1 (no)
JP (1) JP3157842B2 (no)
KR (1) KR100331775B1 (no)
CN (1) CN100363377C (no)
AT (2) ATE234323T1 (no)
AU (1) AU726597B2 (no)
BR (1) BR9711444A (no)
CA (1) CA2264155C (no)
CZ (1) CZ296855B6 (no)
DE (2) DE69705312T2 (no)
DK (2) DK0920438T3 (no)
ES (2) ES2189330T3 (no)
GE (1) GEP20012419B (no)
GR (1) GR3036332T3 (no)
HK (1) HK1020967A1 (no)
HU (1) HU226057B1 (no)
IL (2) IL128652A0 (no)
NO (3) NO312679B1 (no)
NZ (3) NZ505428A (no)
PL (1) PL187635B1 (no)
PT (1) PT920438E (no)
TR (2) TR200202287T2 (no)
UA (1) UA62936C2 (no)
WO (1) WO1998008855A2 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
EP1181291A2 (en) * 1999-05-25 2002-02-27 The Penn State Research Foundation Dna methyltransferase inhibitors
EP1420021A1 (en) * 1999-05-25 2004-05-19 The Penn State Research Foundation DNA Methyltransferase inhibitors
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6576620B2 (en) * 1999-12-03 2003-06-10 Cv Therapeutics, Inc. Method of identifying partial adenosine A1 receptor agonists
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
KR20030040443A (ko) * 2000-09-08 2003-05-22 씨브이 쎄러퓨틱스, 인코포레이티드 항부정맥제로서의 퓨린 리보사이드
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20050227933A1 (en) * 2001-11-29 2005-10-13 Benkovic Stephen J Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
JP4138662B2 (ja) * 2002-01-10 2008-08-27 ザ・ペンシルバニア・ステイト・リサーチ・フアウンデイシヨン アルキルジアリールボリネートおよび錯化ジアリールボロン酸を調製するための方法。
US7144871B2 (en) 2002-02-19 2006-12-05 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
MXPA04010285A (es) * 2002-04-18 2005-02-03 Cv Therapeutics Inc Metodo para tratar arritmias que comprende la administracion de un agonista de adenosina a1 con un bloqueador beta, bloqueador del canal de calcio o un glucosido cardiaco.
ES2273008T3 (es) 2002-05-17 2007-05-01 Neurogen Corporation Derivados de imidazol con anillos fusionados sustituidos: ligandos de receptores gaba sba/sb.
KR20050097971A (ko) * 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
AU2004238217A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US6881851B1 (en) * 2004-04-21 2005-04-19 Eastman Chemical Company Preparation of tetrahydro-3-furoic acid
KR101267202B1 (ko) * 2004-05-26 2013-05-24 이노텍 파마슈티컬스 코포레이션 아데노신 ａ1 수용체 아고니스트로서의 퓨린 유도체 및 이것의 사용 방법
EP1802316B1 (en) * 2004-09-20 2011-11-02 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
CN100451010C (zh) * 2004-12-21 2009-01-14 厦门大学 一种合成(r)-3-氨基四氢呋喃的方法
JP5042996B2 (ja) * 2005-05-19 2012-10-03 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
CN100344768C (zh) * 2005-11-24 2007-10-24 东华大学 一种3－(s)－氨基四氢呋喃的酶法合成方法
WO2007064795A2 (en) * 2005-11-30 2007-06-07 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
WO2009102427A2 (en) 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP2949752B1 (en) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
BR112012017106A2 (pt) 2010-01-11 2018-05-29 Inotek Pharmaceuticals Corp combinação, kit e método de redução de pressão intraocular.
CN110042099A (zh) 2010-03-24 2019-07-23 菲奥医药公司 皮肤与纤维化症候中的rna干扰
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
CA2932753A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2015168605A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3862005A1 (en) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
EP3365446A4 (en) 2015-10-19 2019-06-26 Phio Pharmaceuticals Corp. SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
CN105218490B (zh) * 2015-11-10 2017-05-03 山东川成医药股份有限公司 一种（r）‑3‑氨基四氢呋喃的制备方法
CN115135765A (zh) 2019-11-08 2022-09-30 菲奥医药公司 用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸
EP4085136A1 (en) 2019-12-31 2022-11-09 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
JP2024529025A (ja) 2021-08-04 2024-08-01 フィオ ファーマシューティカルズ コーポレーション 化学修飾されたオリゴヌクレオチド

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) * 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
AU577743B2 (en) * 1984-10-26 1988-09-29 Warner-Lambert Company N6-benzopyrano and benzothiopyrano adenosines
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
KR910700253A (ko) * 1989-01-31 1991-03-14 로버트 제이, 바란 N_6-치환-9-메틸아데닌: 신규한 부류의 아데노신 수용체 길항질
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) * 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer

Also Published As

Publication number Publication date
EP0992510B1 (en) 2003-03-12
NO20020759L (no) 1999-02-19
TR199900377T2 (xx) 1999-05-21
CZ296855B6 (cs) 2006-07-12
PL331853A1 (en) 1999-08-16
NO312679B1 (no) 2002-06-17
NO20020759D0 (no) 2002-02-15
NZ512242A (en) 2004-01-30
DE69719816T2 (de) 2003-12-18
EP1081155A2 (en) 2001-03-07
GR3036332T3 (en) 2001-11-30
NO990787D0 (no) 1999-02-19
GEP20012419B (en) 2001-04-25
NZ334095A (en) 2000-10-27
JP2000501426A (ja) 2000-02-08
CA2264155C (en) 2003-11-18
JP3157842B2 (ja) 2001-04-16
IL128652A0 (en) 2000-01-31
NO322459B1 (no) 2006-10-09
BR9711444A (pt) 2000-01-18
HUP0001640A3 (en) 2002-04-29
CA2264155A1 (en) 1998-03-05
PL187635B1 (pl) 2004-08-31
AU726597B2 (en) 2000-11-16
PT920438E (pt) 2001-10-30
DK0992510T3 (da) 2003-07-07
ATE234323T1 (de) 2003-03-15
EP0920438A2 (en) 1999-06-09
ES2189330T3 (es) 2003-07-01
DE69705312D1 (de) 2001-07-26
KR20000035867A (ko) 2000-06-26
KR100331775B1 (ko) 2002-04-09
DK0920438T3 (da) 2001-09-10
WO1998008855A2 (en) 1998-03-05
NO990787L (no) 1999-02-19
CN100363377C (zh) 2008-01-23
DE69705312T2 (de) 2001-10-11
AU4080997A (en) 1998-03-19
EP0992510A1 (en) 2000-04-12
NZ505428A (en) 2005-03-24
US5789416B1 (en) 1999-10-05
ES2157593T3 (es) 2001-08-16
HU226057B1 (en) 2008-04-28
IL128652A (en) 2008-06-05
WO1998008855A3 (en) 1998-09-03
NO20020758L (no) 1999-02-19
CN1234803A (zh) 1999-11-10
EP1081155A3 (en) 2003-05-02
TR200202287T2 (tr) 2003-01-21
HUP0001640A2 (hu) 2001-05-28
EP0920438B1 (en) 2001-06-20
UA62936C2 (en) 2004-01-15
HK1020967A1 (en) 2000-05-26
US5789416A (en) 1998-08-04
DE69719816D1 (de) 2003-04-17
CZ61499A3 (cs) 1999-10-13
ATE202361T1 (de) 2001-07-15

Similar Documents

Publication Publication Date Title
NO20020758L (no) N&lt;o&gt;6&lt;/o&gt; heterocykliske substituerte adenosinderivater
BR9711262A (pt) Derivados 6,6 substituido hetero biciclicos
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
DK0831829T3 (da) Heterocykliske, ringkondenserede pyrimidinderivater
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
DK0920429T3 (da) Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
NL300203I2 (nl) Antiviraal werkzame heterocyclische azahexaan-derivaten.
DE59501802D1 (de) Substituierte 1H-3-Aryl-pyrrolidin-2,4-dion-Derivate
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
ATE231847T1 (de) Substituierte 1,2,3,4- tetrahydronaphthalinderivate
PT843679E (pt) Derivados da1-(piperidinil 1,2-disubstituido)-(4-imidazole fundido)-piperidina
FR11C0047I2 (fr) Acides 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-(4.3.0)-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinocarboxyliques eventuellement substitues et leurs derives
TR199802607A3 (tr) Alkil-veya benzil türevlerinin alkillenmesine yönelik usul.
BR9609310A (pt) Derivados de 1,3-OXA(TIA)ZINA
ATE240941T1 (de) 1,25-dihydroxy-16,22,23-trisdehydro- cholecalciferol-derivate
ATE214063T1 (de) Heterocyclische substituierte pyrrolidinamid- derivate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees